 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
17 August 1999 | Volume 131 Issue 4 | Pages 247-255
Background: Pancreatic cancer, the fourth most common cause of cancer death in the United States, is hereditary in an estimated 10% of cases. Surveillance of patients with a familial predisposition for pancreatic cancer has not been systematically evaluated.
Objective: To develop a surveillance program that can identify and treat patients who have precancerous conditions of the pancreas and a family history of pancreatic cancer.
Design: Prospective cohort study.
Setting: University medical center.
Patients: 14 patients from three kindreds with a history of pancreatic cancer.
Interventions: Endoscopic ultrasonography, endoscopic retrograde cholangiopancreatography (ERCP), spiral computed tomography, and serum carcinoembryonic antigen and CA19-9 analysis were performed in all patients. Four affected patients were tested for the K- ras mutation.
Main Outcome Measurement: Pancreatic dysplasia was determined by histologic evaluation.
Results: Seven of the 14 patients were believed to have dysplasia on the basis of clinical history and abnormalities on endoscopic ultrasonography and ERCP and were referred for pancreatectomy. All 7 patients had histologic evidence of dysplasia in pancreatectomy specimens. Findings on endoscopic ultrasonography were subtle, nonspecific, and similar to those seen in patients with chronic pancreatitis. Findings on ERCP ranged from mild and focal side-branch duct irregularities and small sacculations to main-duct strictures and grapelike clusters of saccules. Some of these changes are typical of chronic pancreatitis, but others are more distinctive. Spiral computed tomography and serum tumor markers had low sensitivity in the detection of pancreatic dysplasia. Analysis for the K- ras mutation yielded positive results in 3 of 4 patients with dysplasia.
Conclusions: Thorough screening of patients with a family history of pancreatic cancer is feasible. Clinical data combined with imaging studies (endoscopic ultrasonography and ERCP) can be used to identify high-risk patients who have dysplasia. The role of molecular genetic testing is uncertain at this time.
Author and Article Information
From University of Washington, Seattle, Washington.
Requests for Reprints: Teresa A. Brentnall, MD, Division of Gastroenterology, Box 356424, University of Washington, Seattle, WA 98195; e-mail, teribr{at}u.washington.edu.
Current Author Addresses: Drs. Brentnall and Kimmey: Division of Gastroenterology, Box 356424, University of Washington, Seattle, WA 98195.
Drs. Bronner and Haggitt: Department of Pathology, Box 356100, University of Washington, Seattle, WA 98195.
Dr. Byrd: Department of Surgery, Box 356410, University of Washington, Seattle, WA 98195. ARTICLE
Early Diagnosis and Treatment of Pancreatic Dysplasia in Patients with a Family History of Pancreatic Cancer
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  W. D. Foulkes Inherited Susceptibility to Common Cancers N. Engl. J. Med., November 13, 2008; 359(20): 2143 - 2153. [Full Text] [PDF]
|
|
|
|
 |
|
 R. E Brand, M. M Lerch, W. S Rubinstein, J. P Neoptolemos, D. C Whitcomb, R. H Hruban, T. A Brentnall, H. T Lynch, M. I Canto, and Participants of the Fourth International Symposium Advances in counselling and surveillance of patients at risk for pancreatic cancer Gut, October 1, 2007; 56(10): 1460 - 1469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Gullo, M Migliori, P Fusaroli, and G Caletti Familial association of benign pancreatic hyperenzymaemia and pancreatic cancer Gut, September 1, 2007; 56(9): 1323 - 1324. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Wang, S. Chen, K. A. Brune, R. H. Hruban, G. Parmigiani, and A. P. Klein PancPRO: Risk Assessment for Individuals With a Family History of Pancreatic Cancer J. Clin. Oncol., April 10, 2007; 25(11): 1417 - 1422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jimeno and M. Hidalgo Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol. Cancer Ther., April 1, 2006; 5(4): 787 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Matsubayashi, M. Canto, N. Sato, A. Klein, T. Abe, K. Yamashita, C. J. Yeo, A. Kalloo, R. Hruban, and M. Goggins DNA Methylation Alterations in the Pancreatic Juice of Patients with Suspected Pancreatic Disease Cancer Res., January 15, 2006; 66(2): 1208 - 1217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Koopmann, C. N. W. Rosenzweig, Z. Zhang, M. I. Canto, D. A. Brown, M. Hunter, C. Yeo, D. W. Chan, S. N. Breit, and M. Goggins Serum Markers in Patients with Resectable Pancreatic Adenocarcinoma: Macrophage Inhibitory Cytokine 1 versus CA19-9 Clin. Cancer Res., January 15, 2006; 12(2): 442 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N T van Heek, S J Clayton, P D J Sturm, J Walker, D J Gouma, L A Noorduyn, G J A Offerhaus, and J C Fox Comparison of the novel quantitative ARMS assay and an enriched PCR-ASO assay for K-ras mutations with conventional cytology on endobiliary brush cytology from 312 consecutive extrahepatic biliary stenoses J. Clin. Pathol., December 1, 2005; 58(12): 1315 - 1320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Goggins Molecular Markers of Early Pancreatic Cancer J. Clin. Oncol., July 10, 2005; 23(20): 4524 - 4531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Koopmann, M. Goggins, R. H. Hruban, H. Tsao, A. J. Sober, and K. B. Niendorf Case 7-2004: Hereditary Melanoma and Pancreatic Cancer N. Engl. J. Med., June 17, 2004; 350(25): 2623 - 2624. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gangi, J. G. Fletcher, M. A. Nathan, J. A. Christensen, W. S. Harmsen, B. S. Crownhart, and S. T. Chari Time Interval Between Abnormalities Seen on CT and the Clinical Diagnosis of Pancreatic Cancer: Retrospective Review of CT Scans Obtained Before Diagnosis Am. J. Roentgenol., April 1, 2004; 182(4): 897 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Koopmann, P. Buckhaults, D. A. Brown, M. L. Zahurak, N. Sato, N. Fukushima, L. J. Sokoll, D. W. Chan, C. J. Yeo, R. H. Hruban, et al. Serum Macrophage Inhibitory Cytokine 1 as a Marker of Pancreatic and Other Periampullary Cancers Clin. Cancer Res., April 1, 2004; 10(7): 2386 - 2392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Koopmann, N. S. Fedarko, A. Jain, A. Maitra, C. Iacobuzio-Donahue, A. Rahman, R. H. Hruban, C. J. Yeo, and M. Goggins Evaluation of Osteopontin as Biomarker for Pancreatic Adenocarcinoma Cancer Epidemiol. Biomarkers Prev., March 1, 2004; 13(3): 487 - 491. [Abstract] [Full Text]
|
|
|
|
|
|
J. Koopmann, Z. Zhang, N. White, J. Rosenzweig, N. Fedarko, S. Jagannath, M. I. Canto, C. J. Yeo, D. W. Chan, and M. Goggins Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry Clin. Cancer Res., February 1, 2004; 10(3): 860 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Parker, S. R. Florell, A. Alexander, J. A. DiSario, P. J. Shami, and S. A. Leachman Pancreatic Carcinoma Surveillance in Patients With Familial Melanoma Arch Dermatol, August 1, 2003; 139(8): 1019 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Murphy, K. A. Brune, C. Griffin, J. E. Sollenberger, G. M. Petersen, R. Bansal, R. H. Hruban, and S. E. Kern Evaluation of Candidate Genes MAP2K4, MADH4, ACVR1B, and BRCA2 in Familial Pancreatic Cancer: Deleterious BRCA2 Mutations in 17% Cancer Res., July 1, 2002; 62(13): 3789 - 3793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kern, R. Hruban, M. A. Hollingsworth, R. Brand, T. E. Adrian, E. Jaffee, and M. A. Tempero A White Paper: The Product of a Pancreas Cancer Think Tank Cancer Res., June 1, 2001; 61(12): 4923 - 4932. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schenk, A. G. Schwartz, E. O'Neal, M. Kinnard, J. K. Greenson, J. P. Fryzek, G. S. Ying, and D. H. Garabrant Familial Risk of Pancreatic Cancer J Natl Cancer Inst, April 18, 2001; 93(8): 640 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Tersmette, G. M. Petersen, G. J. A. Offerhaus, F. C. Falatko, K. A. Brune, M. Goggins, E. Rozenblum, R. E. Wilentz, C. J. Yeo, J. L. Cameron, et al. Increased Risk of Incident Pancreatic Cancer Among First-degree Relatives of Patients with Familial Pancreatic Cancer Clin. Cancer Res., March 1, 2001; 7(3): 738 - 744. [Abstract] [Full Text]
|
|
|
|
|
|
E EFTHIMIOU, T CRNOGORAC-JURCEVIC, N R LEMOINE, and T A BRENTNALL Inherited predisposition to pancreatic cancer Gut, February 1, 2001; 48(2): 143 - 147. [Full Text] [PDF]
|
|
|
|
|
|
R. H. Hruban, M. Goggins, J. Parsons, and S. E. Kern Progression Model for Pancreatic Cancer Clin. Cancer Res., August 1, 2000; 6(8): 2969 - 2972. [Full Text]
|
|
|
|
 |
|
 Correction: Pancreatic Dysplasia Ann Intern Med, March 7, 2000; 132(5): 419 - 419. [Full Text] [PDF]
|
|
|
|
 |
|
 Early Identification of Pancreatic Cancer? Journal Watch (General), August 27, 1999; 1999(827): 2 - 2. [Full Text]
|
|
Article
